

Mackenzie US Mid Cap Opportunities Fund

Fund snapshot

Inception date	05/27/2020
AUM (millions in CAD)	1705.1
Mangement Fee	0.80%
MER	1.05%
Benchmark	Russell Mid Cap
CIFSC Category	US Small/Mid Cap Equity
Risk Rating	Medium
Lead portfolio manager	Phil Taller
Investment exp. Since	1991
Target # of holdings	25-50

Strategy Overview

• The Fund seeks to provide long-term capital growth and a reasonable rate of return by investing primarily in equity securities of mid-capitalization companies in the United States.

• The Fund seeks companies with strong management, good growth prospects and attractive financial metrics.

• Emphasis is also placed on paying reasonable prices for the growth that companies in the portfolio are expected to achieve.

Trailing returns %



Calendar returns %



	2023	2022	2021
Excess return	-2.0	-6.5	5.1
% of peers beaten	47	31	75



Portfolio characteristics

	Portfolio	Benchmark
# of holdings	30	807
% top 10 holdings	49.4	6.2
Weighted average market cap	28,263.4	37,940.0
EPS growth (FY E)	14.0	14.9
Dividend yield	0.4	1.6
FCF margin	16.3	13.7
P/E Trailing 12M	28.9	20.6
P/E (forecast)	22.5	18.3
Net debt/EBITDA	0.5	1.6
ROE (latest FY)	15.1	15.2

Performance metrics (3 year trailing)

Portfolio	Benchmark
15.0	15.4
-0.1	0.2
5.4	-
-0.8	-
-4.0	-
0.9	-
89.6	-
108.5	-
	15.0 -0.1 5.4 -0.8 -4.0 0.9 89.6

Sector allocation

Sector	Portfolio	Benchmark	Relative Weight
Financials	8.7	16.2	-7.5
Energy	-	5.1	-5.1
Materials	-	5.5	-5.5
Industrials	25.3	19.8	5.5
Information Technology	27.5	14.0	13.5
Communication Services	-	3.5	-3.5
Utilities	-	5.5	-5.5
Consumer Staples	-	3.2	-3.2
Consumer Discretionary	2.7	10.4	-7.7
Real Estate	4.0	7.5	-3.5
Health Care	27.5	9.3	18.2
Other	4.3	-	4.3

Country allocation

Country	Portfolio	Benchmark	RelativeWeight
United States	95.7	99.6	-3.9
Argentina	-	0.1	-0.1
Canada	-	0.1	-0.1
Ireland	-	0.2	-0.2
Other	4.3	-	4.3

Regional breakdown

Region	Portfolio	Benchmark	Relative Weight
United States	95.7	99.6	-3.9
Canada	-	0.1	-0.1
International	-	0.2	-0.2
Other	4.3	0.1	4.2

Currency exposure

Region	Gross	Benchmark
CAD	-	-
USD	100	100



Top 10 holdings

Security name	Country	Sector	Weight
ExlService Holdings, Inc.	United States	Industrials	5.2
DexCom, Inc.	United States	Health Care	5.1
Vontier Corp	United States	Information Technology	5.1
Bio-Techne Corporation	United States	Health Care	5.0
Cirrus Logic, Inc.	United States	Information Technology	5.0
Charles River Laboratories International, Inc.	United States	Health Care	4.6
Akamai Technologies, Inc.	United States	Information Technology	4.4
HealthEquity Inc	United States	Health Care	4.4
MAXIMUS, Inc.	United States	Industrials	4.3
Broadridge Financial Solutions, Inc.	United States	Industrials	4.2

Security level contributors and detractors

	Security	Average Relative weight (%)	% Contribution to return
	Cirrus Logic, Inc.	4.9	1.8
Contributors Westinghouse Air Brake Technologies Corporation		3.7	0.6
	HealthEquity Inc	4.0	0.3
	CoStar Group, Inc.	3.5	-0.9
Detractors	DexCom, Inc.	4.7	-1.0
	Charles River Laboratories International, Inc.	4.9	-1.3

Sector attribution relative to the benchmark

	Sector	Average Relative Al weight (%)	location Effect (%)	Selection Effect (%)	Total Effect (%)
	Industrials	6.2	-0.1	1.5	1.5
	Consumer Discretionary	-7.1	0.2	0.2	0.4
	Financials	-8.1	0.0	0.3	0.3
	Information Technology	14.7	0.6	-1.2	-0.6
Detractors	Real Estate	-3.6	-0.1	-1.0	-1.1
	Health Care	16.7	-0.9	-0.5	-1.3



Commentary

GROWTH – US MID CAP OPP

1) QFR Highlights

Our presence in various life sciences markets is congruent with our strategy to remain under weighted in cyclical exposures. Recent economic releases, like the US employment statistics, have been weak. We remain positioned with a relatively low exposure to more cyclical businesses, and we trimmed weightings in some of these holdings where the market was more optimistic earlier in the second quarter.

We continue to maintain an overweight in the Information Technology, Health Care and Industrials sectors. In fact, we have increased our exposure in Health Care from 24% to 27%. We believe that the secular growth available in those sectors will serve us well. We have reduced our exposure to consumer discretionary owing to its cyclical nature along with the fact that there has been a strain on consumers due to inflation and higher interest rates.

We focus mainly on free cash flow as a metric for company valuations. This measure has become even more important in recent years given the increase in interest rates and also as companies have moved increasingly to present earnings in an "adjusted" fashion, which may obscure reality. We continue to maintain a concentrated portfolio of approximately 30 high quality businesses that despite being smaller in market cap, are often leaders (top 3 players) in the markets they serve.

2) Fund Performance

For Q2 of this year, the funds gross return was -3.26%, while underperforming the benchmark (Russell Midcap) return of -2.33%.

Sector allocation effect in Information Technology, Materials and stock selection within the Industrials, Financials sectors contributed to relative positive performance while allocation effect in Healthcare and Utilities in conjunction with stock selection within the Information Technology and Real Estate detracted performance.

In the sector allocations mentioned above we were overweight in Information Technology, Industrials and Healthcare while being underweight in the remaining sectors.

3) Security contributors

The top contributors in the second quarter of 2024 were Cirrus Logic, Inc., Westinghouse Air Brake Technologies Corporation and HealthEquity Inc..

4) Security detractors

The top detractors in the second quarter of 2024 were Charles River Laboratories International, Inc., CoStar Group, Inc., DexCom, Inc. and Akamai Technologies, Inc..

5) Portfolio activities

We added new positions and increased current ones within the Health Care and Information Technology sectors while decreasing positions within the Consumer Discretionary and Industrial sectors. We continue to look at businesses within the Information Technology sector that are helping companies automate their processes while health care names (drug developers) are seeing an uptick in business activity and hence an interest within our holdings. Staying true to our endeavour to reduce exposure to cyclicals, we have reduced positions in the Consumer Discretionary Sector.

6) Market overview

The U.S. markets over the last quarter have seen a continued rally in the stock prices of the largest U.S. companies by market capitalization, concentrated in the Technology Sector. We believe that the US economy, like many others, already faced structural challenges in the form of high debt levels and slow growth in the working age population. As we navigate 2024, consumers are dealing with elevated interest rates and inflation and so we remain cautious about consumer balance sheets and spending behaviour. With that macro-economic backdrop, we believe that in the long term the world may continue to proceed in a lower growth environment compared to history.

While we do not attempt to forecast near-term economic growth, the current tightening of financial conditions may slow the global economy for a period. We try to be realistic about what companies can achieve in a more challenging environment.

We don't think anybody really knows what the level of ongoing inflation will be, nor what impact it might have on markets.

We do believe that many of our companies offer high value-added products and services, and this should give them reasonable pricing power.



Commentary

GROWTH – US MID CAP OPP

7) Outlook and Positioning

We believe that there may be increased investments in communications, Cloud and public infrastructure, physical and digital security, data analytics, regional supply chains in many industries, commerce, pharmaceutical and medical technology research, the Internet of Things, automation and robotics, online services, advancements in semiconductor, hardware, and network capability. We will be looking for ways to participate in these opportunities as equity markets evolve.

More recently we have become interested in diagnostics. The reality in the diagnostics market is that a company needs more than just good science. That is a necessary thing, but a diagnostics business also needs to be good at gathering data and

evidence, dealing with regulatory compliance and testing guidelines, obtaining reimbursement for tests (not a given since payers try to avoid writing cheques as long as possible), and targeting solid financial results.

We believe companies will seek to invest in new technology and services that can help them participate in a global trend towards digital transformation that can help them be more agile and secure in their operations. The use of data to understand trends should only become more important over time. There may also be increased demand for outsourced business services. We think several of our companies can assist in this effort.

We continue to maintain an overweight in the Industrials, Technology and Health Care sectors. We believe that the secular growth available in those sectors will serve us well. We continue to maintain a low exposure to cyclicals. This change was driven by what we perceived as an overall optimistic tone that didn't reflect the possibility of a slowdown, which may or may not happen.

Our presence in various life sciences markets is congruent with our strategy to remain under weighted in cyclical exposures. Recent economic releases, like the US employment statistics, have been weak. We remain positioned with a relatively low exposure to more cyclical businesses, and we trimmed weightings in some of these like Wabtec where the market was more optimistic earlier in the second quarter.

What we aim to do is to know as many great businesses as we can and learn what they might be worth. When markets offer us attractive share prices for these businesses, we become buyers.

We focus most of our attention on owning innovative secular growth businesses. These types of companies offer products and services that make the world better, cheaper, and faster – enabling them to grow at a faster pace than the overall economy. We see this as a more "all weather" approach – our companies can do well in a rising economy, but also perform relatively better in a difficult economy.

We focus mainly on free cash flow as a metric for company valuations. This measure has become even more important in recent years, as companies have moved increasingly to present earnings in an "adjusted" fashion, which may obscure reality. In our view, accounting risk has risen, and we believe securities regulators are becoming increasingly concerned with these "adjusted" disclosures based on recent guidance.

Market Cap Breakdov	wn:	Sector Breakdown:	
Mkt Cap Bucket	Weight	Sector	Weight
<usd\$4 billion:<="" td=""><td>1.58%</td><td>Communication Services</td><td>0.00%</td></usd\$4>	1.58%	Communication Services	0.00%
USD\$4-5 Billion:	0.00%	Consumer Discretionary	2.71%
USD\$5-7.5 Billion:	30.01%	Consumer Staples	0.00%
USD\$7.5-10 Billion:	4.36%	Energy	0.00%
USD\$10- 45 Billion:	50.02%	Financials	8.72%
>USD\$45 Billion:	10.05%	Health Care	27.48%
		Industrials	25.53%
		Information Technology	27.56%
		Materials	0.00%
		Real Estate	4.02%
		Utilities	0.00



Commentary

GROWTH – US MID CAP OPP

8) Stock stories

DexCom Inc.

- A long time holding in the Small-Mid Fund repurchased by the team but this time in the Mid Cap Opportunities Fund.
- The team has known the company and its management team for many years.
- It is the dominant company in what has effectively become a duopoly in Continuous Glucose Monitoring (CGM).

• Expansion of the market keeps growth high – moving from Type 1 diabetics to Type 2 insulin-dependant diabetics and even other populations over time.

• Each generation of Dexcom's CGM becomes smaller, lighter and easier to use.

Akamai Technologies

• The backbone of the internet. The company speeds up content delivery through their web accelerating services, provide cloud agnostic • security solutions, and offer edge computing capabilities.

- Akamai delivers daily web traffic reaching more than 120 terabytes per second.
- Highly distributed content delivery network (CDN) with over 340,000 servers in more than 135 countries.
- Edge computing is an area that is small today but with a big future in our view.
- Akamai can save clients millions of dollars in "egress fees" or data access fees compared to the traditional hyperscalers
- Working in the digital world, Akamai analyzes 290 TB of new attack data every day.

• Secular grower that benefits from Internet-based TV and video consumption and personal business, such as banking and shopping, being conducted online.

Westinghouse Air Brake Technologies Corp

- Westinghouse Air Brake Technologies Corp is a provider of value-added, technology-based products and services for the rail industry.
- It provides its products and services through two main business segments, the Freight and Transit.
- Safety of train operations is an ongoing concern for rail companies and Wabtec can provide all the equipment and parts to ensure safety and reliability for a train.

Charles River Laboratories International Inc

- Charles River Laboratories is a leading preclinical development and drug safety company.
- They worked on over 85% of the FDA-approved novel drugs in 2021.
- The company is expanding into the area of cell and gene therapy (CGT) to accelerate growth

• CRL has strong pricing power and the company is starting to see a rebound of activity with improvements in biotech funding and M&A activity in the biopharma space.

Vontier Corp

• Vontier serves the retail fueling (69% of revenue), auto repair (22%), telematics (7%), and traffic control (2%) markets.

• Next time you go to the gas station to fill up the car, the chances the fueling system and integrated POS system at the store belonging to Vontier are very high.

• A secondary business that they run is a car repair mobile service. The business is called Matco, they provide vans equipped with all the tools to repair cars on the go.

• Vontier also has a stake in EV chargers and have made acquisitions on that front.



Commissions, trailing commissions, management fees, and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns as of including changes in share value and reinvestment of all distributions and does not take into account sales, redemption, distribution, or optional charges or income taxes payable by any security holder that would have reduced returns.

Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. Index performance does not include the impact of fees, commissions, and expenses that would be payable by investors in the investment products that seek to track an index. This document may contain forward-looking information which reflect our or third party current expectations or forecasts of future events. Forward-looking information is inherently subject to, among other things, risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed herein. These risks, uncertainties and assumptions include, without limitation, general economic, political and market factors, interest and foreign exchange rates, the volatility of equity and capital markets, business competition, technological change, changes in government regulations, changes in tax laws, unexpected judicial or regulatory proceedings and catastrophic events. Please consider these and other factors carefully and not place undue reliance on forward-looking information. The forward-looking information contained herein is current only as of . There should be no expectation that such information will in all circumstances be updated, supplemented or revised whether as a result of new information, changing circumstances, future events or otherwise.

The content of this commentary (including facts, views, opinions, recommendations, descriptions of or references to, products or securities) is not to be used or construed as investment advice, as an offer to sell or the solicitation of an offer to buy, or an endorsement, recommendation or sponsorship of any entity or security cited. Although we endeavour to ensure its accuracy and completeness, we assume no responsibility for any reliance upon it.

Standard deviation provides a measure of the variability of returns that have occurred relative to the average return. The higher the standard deviation, the greater is the range of returns that has been experienced. Standard deviation is commonly used as a measure of risk.

Percentile rankings are from Morningstar Research Inc., an independent research firm, based on the category and reflect the performance of the for the 3-month, 1-, 3-, 5-, and 10-year periods as of . The percentile rankings compare how a fund has performed relative to other funds in a particular category and are subject to change monthly. The number of funds for Mackenzie for each period are as follows: one year –271; three years –233 ; five years – 184 ; ten years – 120.

© Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Morningstar data is shown as of the most recent reporting period by each fund family. Allocations may not equal 100% and will vary overtime. Assets contained within "Other" category are not classified by Morningstar. All information presented in this tool is for informational purposes only and is not intended to be investment advice. The information is not meant to be an offer to sell or a recommendation to buy any investment product. Unless otherwise noted, performance is shown before sales charge. For more fund information, click the POS Documents link.

All information is historical and not indicative of future results. Current performance may be lower or higher than the quoted past performance, which cannot guarantee results. Share price, principal value, and return will vary, and you may have a gain or a loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. Performance may not reflect any expense limitation or subsidies currently in effect. Short-term trading fees may apply. To obtain the most recent month-end performance, visit Morningstar.com.

This material is for informational and educational purposes only. It is not a recommendation of any specific investment product, strategy, or decision, and is not intended to suggest taking or refraining from any course of action. It is not intended to address the needs, circumstances, and objectives of any specific investor. Mackenzie Investments, which earns fees when clients select its products and services, is not offering impartial advice in a fiduciary capacity in providing this sales and marketing material. This information is not meant as tax or legal advice. Investors should consult a professional advisor before making investment and financial decisions and for more information on tax rules and other laws, which are complex and subject to change.

© Mackenzie Investments. All rights reserved.